PPM-012 - Impact of CYP450 Genotype and patient adherence on tamoxifen and its metabolites concentrations: A cross-sectional clinical investigation

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPM-012
• By: HUANG, Hsuan Yu (Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taiwan)
• Co-author(s): Ms Hsuan Yu Huang (Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan)
  Associate Professor Shu Wen Lin (Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan / School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan / Department of Pharmacy, National Taiwan University Hospital Cancer Center, Taipei, Taiwan)
  Professor Ching Hua Ko (School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan)
  Doctor Chiao Lo (Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)
  Doctor Po Han Lin (Institute of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan / Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan)
  Doctor Chiun Sheng Huang (Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)
  Doctor Pei Lung Chen (Institute of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan / Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan)
  Professor Li Jiuan Shen (Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan / School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan / Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan)
  
• Abstract:

  Introduction
  Tamoxifen, a prodrug activated by cytochrome P450 isoforms, is widely used as an endocrine therapy for hormone receptor-positive breast cancer patients. While the standard dose is 20 mg/day, this one-size-fits-all approach does not account for individual patient characteristics, resulting in high variability in concentrations of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login